KR102116320B1 - 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도 - Google Patents

타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도 Download PDF

Info

Publication number
KR102116320B1
KR102116320B1 KR1020187008233A KR20187008233A KR102116320B1 KR 102116320 B1 KR102116320 B1 KR 102116320B1 KR 1020187008233 A KR1020187008233 A KR 1020187008233A KR 20187008233 A KR20187008233 A KR 20187008233A KR 102116320 B1 KR102116320 B1 KR 102116320B1
Authority
KR
South Korea
Prior art keywords
amino acid
ser
leu
thr
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187008233A
Other languages
English (en)
Korean (ko)
Other versions
KR20180038557A (ko
Inventor
티아닝 장
콴 유안
서란 구오
잉 장
틴지안 자오
준 장
닝샤오 시아
Original Assignee
시아먼 유니버시티
양셍탕 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시아먼 유니버시티, 양셍탕 컴퍼니 리미티드 filed Critical 시아먼 유니버시티
Publication of KR20180038557A publication Critical patent/KR20180038557A/ko
Application granted granted Critical
Publication of KR102116320B1 publication Critical patent/KR102116320B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020187008233A 2015-08-25 2016-08-24 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도 Active KR102116320B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510523187 2015-08-25
CN201510523187.8 2015-08-25
PCT/CN2016/096481 WO2017032303A1 (zh) 2015-08-25 2016-08-24 一种用于展示目的多肽的多肽载体及其用途

Publications (2)

Publication Number Publication Date
KR20180038557A KR20180038557A (ko) 2018-04-16
KR102116320B1 true KR102116320B1 (ko) 2020-05-29

Family

ID=58099609

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187008233A Active KR102116320B1 (ko) 2015-08-25 2016-08-24 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도

Country Status (8)

Country Link
US (1) US10548973B2 (enExample)
EP (1) EP3342866B1 (enExample)
JP (1) JP6863966B2 (enExample)
KR (1) KR102116320B1 (enExample)
CN (1) CN106480070B (enExample)
AU (1) AU2016313660B2 (enExample)
BR (1) BR112018003580A2 (enExample)
WO (1) WO2017032303A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102441211B1 (ko) * 2014-06-26 2022-09-07 더 락커펠러 유니버시티 아시네토박터 라이신
US10987418B2 (en) 2017-02-17 2021-04-27 Xiamen University Polypeptide carrier for presenting target polypeptide and uses thereof
JP7607289B2 (ja) 2019-05-23 2024-12-27 シァメン・ユニヴァーシティ 新規の抗ｂ型肝炎ウイルス抗体及びその使用
CN111138550B (zh) * 2020-01-06 2022-12-13 国药中生生物技术研究院有限公司 一种重组呼吸道合胞病毒嵌合疫苗及其制备方法和应用
WO2022012539A1 (zh) * 2020-07-17 2022-01-20 养生堂有限公司 一种细胞穿膜肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127554A (zh) * 2010-12-22 2011-07-20 南京农业大学 一种日本脑炎颗粒疫苗及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
US20060094017A1 (en) 2003-02-14 2006-05-04 Conley Anthony J Immunogens for hiv vaccine
US7144712B2 (en) 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CN100537762C (zh) * 2004-06-24 2009-09-09 中国人民解放军军事医学科学院野战输血研究所 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用
CN104211784B (zh) 2013-06-04 2018-05-22 厦门大学 用于制备戊型肝炎病毒样颗粒的蛋白质和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127554A (zh) * 2010-12-22 2011-07-20 南京农业大学 一种日本脑炎颗粒疫苗及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
David C. Whitacre, Expert rev. Vaccines 8(11) 1565-1573 (2009.11.)
F.Schodel 등, J Biotechnol. 44(1-3):91-96 (1996.01.26.)
J.F. Drexler 등, PNAS vol.110, no.40, p.16151-16156 (2013.10.01.)*

Also Published As

Publication number Publication date
AU2016313660A1 (en) 2018-04-12
JP2018533908A (ja) 2018-11-22
BR112018003580A2 (pt) 2018-09-25
EP3342866A4 (en) 2019-02-27
AU2016313660B2 (en) 2019-11-07
WO2017032303A1 (zh) 2017-03-02
EP3342866A1 (en) 2018-07-04
CA2996497A1 (en) 2017-03-02
US10548973B2 (en) 2020-02-04
HK1252980A1 (en) 2019-06-06
KR20180038557A (ko) 2018-04-16
CN106480070B (zh) 2023-10-20
US20190247494A1 (en) 2019-08-15
JP6863966B2 (ja) 2021-04-21
EP3342866B1 (en) 2021-12-15
CN106480070A (zh) 2017-03-08

Similar Documents

Publication Publication Date Title
CN113817029B (zh) 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用
KR102116320B1 (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
KR102777995B1 (ko) 11형 인유두종 바이러스 엘1 단백질의 돌연변이체
WO2025236842A1 (zh) 一种vzv重组蛋白及其制备方法和应用
KR102803235B1 (ko) 타입 39 인유두종 바이러스 l1 단백질의 돌연변이체
US8470372B2 (en) Material with immunogenicity
CN108456686B (zh) 一种用于展示目的多肽的多肽载体及其用途
KR102567627B1 (ko) 인간 유두종 바이러스 타입 16의 l1 단백질의 변이체
JP2022504624A (ja) 拡大された抗原性スペクトルを有するエプスタイン・バーウイルス様粒子
CA2996497C (en) Polypeptide carrier for presenting target polypeptide and uses thereof
US20080069830A1 (en) Dna Sequences, Peptides, Antibodies and Vaccines for Prevention and Treatment of Sars
CN101611144B (zh) 重组病毒蛋白及颗粒
HK1252980B (en) Polypeptide carrier for presenting target polypeptide and uses thereof
JP2021535077A (ja) ヒトパピローマウイルス１８型のｌ１タンパク質の変異体
KR101695518B1 (ko) 호흡기 신시치아 바이러스 범용 백신
JPWO2017122583A1 (ja) ＨＰＶＬ２ペプチド／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症用ワクチン
HK1230514B (zh) Pres1用於制备乙肝疫苗以及治疗慢性乙型肝炎的用途

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20180322

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180322

Comment text: Request for Examination of Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20181207

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190213

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190830

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190213

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190830

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190415

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180322

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191030

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20200519

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20191230

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191002

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190830

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190415

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180322

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200522

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200525

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230427

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250415

Start annual number: 6

End annual number: 6